Abbott Amplatzer Paraclose PVL Occluder Wins FDA Approval

Abbott Announces FDA Approval

Abbott announced on October 28, 2026, that it received U.S. Food and Drug Administration approval for the Amplatzer Paraclose PVL Occluder, according to Securities.

Securities reported that the device is designed to treat paravalvular leak, also known as PVL. The publisher described PVL as backflow of blood around a surgical heart valve.

The reported regulatory event concerns a transcatheter device from Abbott for a condition associated with surgical heart valves. Abbott’s announcement places the Amplatzer Paraclose PVL Occluder among devices intended to address PVL through a transcatheter approach.

Reported Positioning for PVL Treatment

According to Securities, Abbott characterized the implant in its announcement as the first and only transcatheter device approved for this purpose.

The approval and Abbott’s stated positioning center on the use of the device in treating paravalvular leak. Securities identified the product as an implant and described its intended treatment setting as transcatheter.

For medical device sales professionals following cardiovascular and structural heart developments, the announcement is an FDA approval update involving Abbott and its Amplatzer Paraclose PVL Occluder.

Key Details From the Announcement

• Abbott announced the FDA approval on October 28, 2026, Securities reported.
• The approved product is the Amplatzer Paraclose PVL Occluder.
• The device is designed to treat paravalvular leak around a surgical heart valve.
• Abbott described the product as a transcatheter device.
• Abbott characterized the implant as the first and only transcatheter device approved for this purpose, according to Securities.

Securities’ report highlights the FDA approval, the product’s transcatheter design, and its intended role in PVL treatment. Abbott’s announcement provides the basis for the reported first-and-only characterization.